CMPX Compass Therapeutics Forecast, Technical & Fundamental Analysis
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases... Show more
CMPX is expected to report earnings to fall 4.62% to -12 cents per share on November 11
Q3'26
Est.
$-0.12
Q2'26
Missed
by $0.02
Q1'26
Est.
$-0.10
Q4'25
Beat
by $0.01
Q3'25
Beat
by $0.06
The last earnings report on August 06 showed earnings per share of -12 cents, missing the estimate of -10 cents. With 741.31K shares outstanding, the current market capitalization sits at 405.20M.
A.I.dvisor indicates that over the last year, CMPX has been loosely correlated with VCYT. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CMPX jumps, then VCYT could also see price increases.
CMPX in downward trend: price expected to drop as it breaks its higher Bollinger Band on August 12, 2026
CMPX broke above its upper Bollinger Band on August 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 42 similar instances where the stock broke above the upper band. In of the 42 cases the stock fell afterwards. This puts the odds of success at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for CMPX moved out of overbought territory on August 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CMPX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CMPX entered a downward trend on August 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 07, 2026. You may want to consider a long position or call options on CMPX as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CMPX just turned positive on August 07, 2026. Looking at past instances where CMPX's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
CMPX moved above its 50-day moving average on August 07, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CMPX crossed bullishly above the 50-day moving average on August 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CMPX advanced for three days, in of 264 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.440) is normal, around the industry mean (20.047). P/E Ratio (0.000) is within average values for comparable stocks, (24.309). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.844). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (555.556) is also within normal values, averaging (438.506).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CMPX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMPX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
